WaferGen has made changes to its board of directors following the firm's acquisition of IntegenX's next-gen sequencing library prep business. The company has reduced the size of its board of directors to seven from nine. In addition, Robert Schueren, IntegenX's CEO, will join WaferGen's board of directors. Prior to his role at IntegenX, Schueren was vice president and general manager of genomics at Agilent Technologies.
The board also appointed William McKenzie as a director, effective Dec. 30, 2013. Most recently, he served as president and general manager of molecular diagnostics at PerkinElmer.
Scott Davidson and Joseph Pesce, representatives of Great Point Partners, stepped down from the board, effective Dec. 30, 2013.